Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Recent News

Venetoclax Plus Gilteritinib in FLT3-Mutated AML
Ivosidenib Plus Azacitidine in Older Patients With IDH1-Mutated AML
Gilteritinib Versus Chemotherapy in Asian Patients With Resistant AML: Phase III Trial
Using Triplet FLT3 Inhibitor–Based Therapy for Older Patients With AML
Impact of NPM1 and FLT3 Mutations on Prognosis in Patients With AML in Remission
Eprenetapopt Plus Azacitidine in TP53-Mutated AML After Stem Cell Transplantation
ASH 2021: Predictive Potential of Immunosuppressive Phenotypes on Outcomes in AML
ASH 2021: Gilteritinib and Azacitidine in FLT3-Mutated AML
ASH 2021: Updated Overall Survival From QUAZAR AML-001 Trial of Oral Azacitidine in AML in First Remission
ASH 2021: Lower-Intensity Venetoclax-Based Combination Therapy Under Study in AML
Can Immune Response to COVID-19 Produce Antitumor Immunity in Patients With AML?
Pediatric KMT2A-Rearranged AML: CD33-Targeted Agent Focus of Phase III Trial
Treating Relapsed AML With Venetoclax, Azacitidine, and Donor Lymphocyte Infusion
Therapeutic Potential of Enhancing p300 Catalytic Activity in MDS/AML
Fox Chase Cancer Researcher Receives Grant to Investigate LSD1 Inhibitors in AML
ASTRO 2021: Use of Total Marrow and Lymphoid Irradiation Before Chemotherapy in AML
Decitabine Therapy With Priming Regimen Under Study in Poor-Prognosis AML
Clinical Trial Data Model: What Can It Offer Health-Care Professionals Who Treat AML?
Newly Diagnosed Mutant-IDH2 AML: Enasidenib Plus Azacitidine Under Study
Gilteritinib Reevaluated for FLT3-Mutated AML: Follow-up From ADMIRAL Trial
Antileukemic Activity Reported With Double Epigenetic Priming Regimen in Resistant AML
Future Directions in the Management of Newly Diagnosed AML
Can Addition of E-Selectin Antagonist to Chemotherapy Improve Outcomes in Resistant AML?
Have Federal Regulations Improved Racial and Ethnic Disparities in Acute Leukemia Clinical Trials?
Volasertib Plus Cytarabine in Chemotherapy-Ineligible AML: Phase III Findings
Induction Chemotherapy With Intermediate-Dosed Cytarabine for High-Risk AML
Triplet Combination Therapies Under Study for IDH-Mutated AML
SOHO 2021: Exploring Treatment Alternatives to BCL2 Inhibition in AML
SOHO 2021: Optimizing Treatment for Older Patients With AML
SOHO 2021: Novel Combination Therapy Under Study in Newly Diagnosed AML
SOHO 2021: Adding Azacitidine to FLAG Chemotherapy in AML
SOHO 2021: Early Results With Magrolimab Plus Azacitidine in AML
Is Chemotherapy Linked to Deterioration of Oral Health in Patients With AML?
One Man’s Experience With AML, COVID-19, and Allo-HSCT
Can Romyelocel-L Plus G-CSF Reduce Infections in Patients With AML?
Can MRD Guide Postremission Treatment Decisions in Intermediate-Risk AML?
Mixed Results Emerge in Phase II Selinexor Trial in Older Patients With Resistant AML
Novel Monoclonal Antibody and Chemotherapy Combination Under Study in Resistant AML
Japanese Subgroup Analysis of BCL2 Inhibitor Plus Low-Dose Cytarabine in Untreated AML
COVID-19 and Leukemias: Focus on Risk Factors for Poor Outcomes
Absolute Monocyte and Lymphocyte Counts in AML: Prognostic Significance at the Time of Relapse


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.